Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Cognitive deficits, including working memory deficits, are often present in depression and there are currently no effective pharmacological treatments targeting working memory deficits. Papassotiropoulos et al. (2024) has recently demonstrated that fampridine, a potassium channel blocker, can enhance working memory in healthy individuals with lower baseline performance, suggesting it may hold potential for addressing cognitive deficits in clinical populations. The primary aim of this study is to evaluate whether fampridine improves working memory performance in mild to moderate depression
Eligibility Criteria
Inclusion Criteria: * Male or female * Major depressive episode confirmed by the Mini-DIPS. Currently mild to moderate (MADRS: 7-30). * Normotensive (BP: 90/60mmHg - 140/90mmHg). Sufficiently treated hypertensive subjects will be included. * BMI: 19 - 34,9 kg/m2 * Age: 18 - 55 years * Fluent in German * IC as documented by signature Exclusion Criteria: * Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to 4-aminopyridine * Use of potassium channel blockers within the last 3 months * Treatment with OCT 2 inhibitors and -substrates (e.g. cimetidine, propranolol) * Treatment with antidepressants or antipsychotics within the last 3 months and throughout the study period * Current intake of psychoactive drugs (e.g. benzodiazepines, antidepressants, neuroleptics). * Other acute or chronic psychiatric disorder (e.g. psychosis, somatoform disorder, alcohol or drug abuse disorder) * Cognitive impairment (MoCA score \< 25) * MADRS item 10 \> 1 (suicidal